Cohance Lifesciences Limited
1,114words
0turns
0analyst exchanges
0executives
Key numbers — 40 extracted
52.39%
. Crore 5 Financial Snapshot Q3FY21 9MFY21 Growth in Revenue Growth in EBITDA Growth in PAT 52.39% 69.31% 96.21% 15.06% 12.30% 14.99% 6 Key Ratios Q3FY21 Q3FY20 EBIT to Income EBITDA to
69.31%
5 Financial Snapshot Q3FY21 9MFY21 Growth in Revenue Growth in EBITDA Growth in PAT 52.39% 69.31% 96.21% 15.06% 12.30% 14.99% 6 Key Ratios Q3FY21 Q3FY20 EBIT to Income EBITDA to Income
96.21%
ncial Snapshot Q3FY21 9MFY21 Growth in Revenue Growth in EBITDA Growth in PAT 52.39% 69.31% 96.21% 15.06% 12.30% 14.99% 6 Key Ratios Q3FY21 Q3FY20 EBIT to Income EBITDA to Income PAT to
15.06%
apshot Q3FY21 9MFY21 Growth in Revenue Growth in EBITDA Growth in PAT 52.39% 69.31% 96.21% 15.06% 12.30% 14.99% 6 Key Ratios Q3FY21 Q3FY20 EBIT to Income EBITDA to Income PAT to Income
12.30%
Q3FY21 9MFY21 Growth in Revenue Growth in EBITDA Growth in PAT 52.39% 69.31% 96.21% 15.06% 12.30% 14.99% 6 Key Ratios Q3FY21 Q3FY20 EBIT to Income EBITDA to Income PAT to Income 47.98%
14.99%
9MFY21 Growth in Revenue Growth in EBITDA Growth in PAT 52.39% 69.31% 96.21% 15.06% 12.30% 14.99% 6 Key Ratios Q3FY21 Q3FY20 EBIT to Income EBITDA to Income PAT to Income 47.98% 51.11%
47.98%
12.30% 14.99% 6 Key Ratios Q3FY21 Q3FY20 EBIT to Income EBITDA to Income PAT to Income 47.98% 51.11% 40.61% 43.00% 46.00% 31.54% 7 Key Ratios 9MFY21 9MFY20 EBIT to Income EBITDA to
51.11%
14.99% 6 Key Ratios Q3FY21 Q3FY20 EBIT to Income EBITDA to Income PAT to Income 47.98% 51.11% 40.61% 43.00% 46.00% 31.54% 7 Key Ratios 9MFY21 9MFY20 EBIT to Income EBITDA to Income
40.61%
6 Key Ratios Q3FY21 Q3FY20 EBIT to Income EBITDA to Income PAT to Income 47.98% 51.11% 40.61% 43.00% 46.00% 31.54% 7 Key Ratios 9MFY21 9MFY20 EBIT to Income EBITDA to Income PAT to
43.00%
Ratios Q3FY21 Q3FY20 EBIT to Income EBITDA to Income PAT to Income 47.98% 51.11% 40.61% 43.00% 46.00% 31.54% 7 Key Ratios 9MFY21 9MFY20 EBIT to Income EBITDA to Income PAT to Income
46.00%
Q3FY21 Q3FY20 EBIT to Income EBITDA to Income PAT to Income 47.98% 51.11% 40.61% 43.00% 46.00% 31.54% 7 Key Ratios 9MFY21 9MFY20 EBIT to Income EBITDA to Income PAT to Income 44.17%
31.54%
Q3FY20 EBIT to Income EBITDA to Income PAT to Income 47.98% 51.11% 40.61% 43.00% 46.00% 31.54% 7 Key Ratios 9MFY21 9MFY20 EBIT to Income EBITDA to Income PAT to Income 44.17% 47.25%
Advertisement